Lyell Immunopharma (NASDAQ:LYEL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lyell Immunopharma (NASDAQ:LYEL) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

Other analysts have also recently issued reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $44.00 price target on shares of Lyell Immunopharma in a report on Friday, September 11th. Citizens Jmp reiterated a “market outperform” rating and set a $34.00 price objective on shares of Lyell Immunopharma in a research note on Monday, June 15th. Royal Bank Of Canada set a $34.00 target price on shares of Lyell Immunopharma in a research report on Friday, August 14th. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Finally, B. Riley Financial assumed coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma Trading Down 1.1%

LYEL opened at $9.74 on Friday. The firm has a market cap of $238.63 million, a price-to-earnings ratio of -0.76 and a beta of -0.04. Lyell Immunopharma has a 12 month low of $9.60 and a 12 month high of $45.00. The stock has a fifty day moving average price of $13.23 and a 200-day moving average price of $16.22.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. On average, equities research analysts forecast that Lyell Immunopharma will post -7.2 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. MWG Caph Ltd purchased a new stake in Lyell Immunopharma during the 4th quarter worth approximately $31,030,000. Opaleye Management Inc. raised its holdings in shares of Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after buying an additional 264,928 shares during the last quarter. venBio Partners LLC acquired a new stake in shares of Lyell Immunopharma during the second quarter worth $4,744,643. Renaissance Technologies LLC grew its holdings in shares of Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after buying an additional 76,921 shares during the last quarter. Finally, Velan Capital Investment Management LP grew its holdings in shares of Lyell Immunopharma by 2.9% during the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after buying an additional 3,000 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for patients with cancer. The company’s research is aimed at addressing challenges that can limit the effectiveness of cellular immunotherapies, including T-cell exhaustion, inadequate persistence and difficulty penetrating solid tumors.

Lyell uses its cellular reprogramming and genetic engineering technologies to develop therapeutic T cells, including chimeric antigen receptor (CAR) T-cell candidates.